Home/Pipeline/BTX 1801

BTX 1801

Staphylococcus Aureus / MRSA Decolonization (in Hemodialysis Patients)

Pre-clinical / ResearchAntimicrobial gel program focused on preventing bloodstream infections

Key Facts

Indication
Staphylococcus Aureus / MRSA Decolonization (in Hemodialysis Patients)
Phase
Pre-clinical / Research
Status
Antimicrobial gel program focused on preventing bloodstream infections
Company

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is a global healthcare innovator focused on transforming the treatment landscape for common yet underserved dermatological conditions and infections. The company's key achievement is the FDA approval and US commercial launch of Sofdra™, its first-in-class topical anticholinergic for hyperhidrosis, which is also approved and launched in Japan and South Korea through partners. With a mature pipeline targeting acne, rosacea, atopic dermatitis, and antimicrobial resistance (MRSA), and led by a world-class team with extensive dermatology drug development and commercialization expertise, Botanix is strategically positioned to capture significant market opportunities.

View full company profile